21 Dec 2021 11:34
21 December 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Dr Adam Mark Hill, PDMR and Chief Executive Officer, has purchased 5,988 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for £1.67 per share on 21 December 2021.
Following this transaction, Dr Hill has a total interest in the Company of 52,665 Ordinary Shares, representing approximately 0.08 per cent of the Company's issued share capital of 69,137,848.
In addition, Dr Hill holds options over a total of 3,490,862 Ordinary Shares, representing approximately 5.05 per cent of the Company's issued share capital.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Dr Adam Mark Hill | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£1.67 | 5,988 | ||||
d)
| Aggregated information | N/A - single transaction | |||
- Aggregated volume | |||||
- Price | |||||
e)
| Date of the transaction | 21 December 2021 | |||
f) | Place of the transaction | London Stock Exchange, AIM
| |||
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes
+44 (0)20 3705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue both from its portfolio of diagnostic products to detect early-stage cancer and its contract discovery and development service business whose platform delivers actionable insights into therapies to the Company's pharmaceutical and biotech partners.
Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.
Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS business development team are based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.
For more information, visit www.oncimmune.com
Oncimmune (ONC)